7,297 Shares in Exelixis, Inc. $EXEL Bought by Chicago Partners Investment Group LLC

Key Points

• Chicago Partners Investment Group LLC has acquired 7,297 shares of Exelixis, Inc. valued at approximately $331,000 in the 2nd quarter.
• Exelixis reported earnings of $0.75 per share for the last quarter, exceeding the consensus estimate of $0.63, although its revenue decreased by 10.8% compared to the same quarter last year.
• Institutional investors currently own 85.27% of Exelixis stock, indicating strong confidence in the company's future prospects.

Chicago Partners Investment Group LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,297 shares of the biotechnology company's stock, valued at approximately $331,000.

Several other large investors also recently modified their holdings of EXEL. GAMMA Investing LLC grew its holdings in shares of Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock worth $201,000 after acquiring an additional 1,328 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Exelixis by 64.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 110,036 shares of the biotechnology company's stock valued at $4,063,000 after purchasing an additional 43,194 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Exelixis by 13.5% during the first quarter. Janney Montgomery Scott LLC now owns 37,778 shares of the biotechnology company's stock valued at $1,395,000 after purchasing an additional 4,482 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Exelixis by 22.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 84,092 shares of the biotechnology company's stock valued at $3,105,000 after purchasing an additional 15,183 shares in the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new position in Exelixis during the first quarter valued at $233,000. Institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 5.5%

Shares of EXEL stock opened at $38.05 on Friday. Exelixis, Inc. has a 12-month low of $27.86 and a 12-month high of $49.62. The stock's 50-day moving average price is $38.67 and its 200-day moving average price is $40.01. The stock has a market capitalization of $10.24 billion, a price-to-earnings ratio of 18.29, a price-to-earnings-growth ratio of 0.72 and a beta of 0.38.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. During the same period in the previous year, the firm posted $0.84 earnings per share. The business's revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a "buy (b)" rating on shares of Exelixis in a research report on Wednesday, October 8th. Zacks Research downgraded Exelixis from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 26th. The Goldman Sachs Group began coverage on Exelixis in a report on Wednesday, September 17th. They set a "buy" rating and a $47.00 price target on the stock. Truist Financial decreased their price target on Exelixis from $56.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, July 29th. Finally, UBS Group set a $38.00 price target on Exelixis and gave the company a "neutral" rating in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $44.53.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.